Cargando…
Compassionate use of orphan drugs
BACKGROUND: EU regulation 726/2004 authorises manufacturers to provide drugs to patients on a temporary basis when marketing authorisation sought centrally for the entire EU is still pending. Individual Member States retain the right to approve and implement such ‘compassionate use’ programmes which...
Autores principales: | Hyry, Hanna I., Manuel, Jeremy, Cox, Timothy M., Roos, Jonathan C. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546220/ https://www.ncbi.nlm.nih.gov/pubmed/26292942 http://dx.doi.org/10.1186/s13023-015-0306-x |
Ejemplares similares
-
The legal imperative for treating rare disorders
por: Hyry, Hanna I, et al.
Publicado: (2013) -
Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases
por: Koenig, Mary Kay, et al.
Publicado: (2022) -
Compassionate drug use: Current status in India
por: Shetty, Yashashri C., et al.
Publicado: (2020) -
Characterizing expanded access and compassionate use programs for experimental drugs
por: Miller, Jennifer E., et al.
Publicado: (2017) -
Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)